RecruitingPhase 1NCT06525636

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Studying X-linked hypophosphatemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kyowa Kirin Co., Ltd.
Principal Investigator: Kyowa Kirin
Kyowa Kirin, Inc.
Intervention: KK8123(drug)
Enrollment: 24 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2024 – 2028

Study locations (9)

University of California - San Francisco, San Francisco, California, United States
Yale Center for XLH/ Yale University School of Medicine, New Haven, Connecticut, United States
Indiana University School of Medicine University Hospital, Indianapolis, Indiana, United States
Mayo Clinic, Rochester, Minnesota, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Hoptial Bictre, Le Kremlin-Bicêtre, Paris, France
Institute of Osteology and Biomechanics (IOBM), Hamburg, Germany
Universitaetsklinikum Wurzburg, Würzburg, Germany
Hospital Universitario La Paz, Madrid, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06525636 on ClinicalTrials.gov

Other trials for X-linked hypophosphatemia

Additional recruiting or active studies for the same condition.

See all trials for X-linked hypophosphatemia →

← Back to all trials